Characteristics of early and late PTLD development in pediatric solid organ transplant recipients

Transplantation

Volumn 95, Issue 1, 2013, Pages 240-246

  Schober, Tilmann ^a,d   Framke, Theodor ^a   Kreipe, Hans ^a   Schulz, Thomas F ^a   Grohennig, Anika ^a   Hussein, Kais ^a   Baumann, Ulrich ^a   Pape, Lars ^a   Schubert, Stephan ^b   Wingen, Anne Margret ^c   Jack, Thomas ^a   Koch, Armin ^a   Klein, Christoph ^a,d   Maecker Kolhoff, Britta ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Pediatric; Posttransplantation lymphoproliferative disease; Prognostic factors; PTLD; Solid organ transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID; TACROLIMUS;

ADOLESCENT; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHILD; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EVENT FREE SURVIVAL; FEMALE; GERMANY; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INFANT; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PEDIATRICS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; REGISTER; SCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOPROLIFERATIVE DISORDERS; MALE; ORGAN TRANSPLANTATION; RETROSPECTIVE STUDIES;

EID: 84872093147     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318277e344     Document Type: Article

References (30)

1. Everly MJ, Bloom RD, Tsai DE, et al. Posttransplant lymphoproliferative disorder. Ann Pharmacother 2007; 41: 1850.
2. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, et al. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 2009; 13: 54.
3. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipientsV BCSH and BTS guidelines. Br J Haematol 2010; 149: 675.
4. Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group report. Am J Transplant 2012; 12: 3069.
5. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038.
6. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006; 367: 233.
7. Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007; 25: 4902.
8. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell posttransplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196.
9. Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052.
10. Caillard S, Lamy FX, Quelen C, et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12: 682.
11. Ghobrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005; 79: 244.
12. Paranjothi S, Yusen RD, Kraus MD, et al. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J Heart Lung Transplant 2001; 20: 1054.
13. Quinlan SC, Pfeiffer RM, Morton LM, et al. Risk factors for earlyonset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011; 86: 206.
14. Caillard S, Pencreach E, Braun L, et al. Simultaneous development of lymphoma in recipients of renal transplants from a single donor: donor origin confirmed by human leukocyte antigen staining and microsatellite analysis. Transplantation 2005; 79: 79.
15. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
16. Bucuvalas JC, Ryckman FC. Long-term outcome after liver transplantation in children. Pediatr Transplant 2002; 6: 30.
17. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
18. Dayton JD, Richmond ME, Weintraub RG, et al. Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 420.
19. Manlhiot C, Pollock-Barziv SM, Holmes C, et al. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transplant 2010; 29: 648.
20. Schubert S, Renner C, Hammer M, et al. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 2008; 27: 100.
21. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76: 984.
22. Gulley ML, Swinnen LJ, Plaisance KT Jr, et al. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003; 76: 959.
23. Capello D, Rasi S, Oreste P, et al. Molecular characterization of posttransplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. J Pathol 2009; 218: 478.
24. Olagne J, Caillard S, Gaub MP, et al. Post-transplant lymphoproliferative disorders: determination of donor/recipient origin in a large cohort of kidney recipients. Am J Transplant 2011; 11: 1260.
25. Schiffer L, Gendo CH, Wilsdorf N, et al. CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD. Am J Transplant 2012; 12: 1610.
26. Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant 2006; 6: 2735.
27. Trofe J, Buell JF, Beebe TM, et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5: 775.
28. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649.
29. Murphy SB, Fairclough DL, Hutchison RE, et al. Non-Hodgkin's lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989; 7: 186.
30. Shipp MA, Hamington DP, Anderson FL, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987.